- Home
- CLPR vs COEP Comparison
CLPR vs COEP Comparison
Compare CLPR & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLPR
- COEP
- Stock Information
- Founded
- CLPR 2015
- COEP 2017
- Country
- CLPR United States
- COEP United States
- Employees
- CLPR N/A
- COEP N/A
- Industry
- CLPR Real Estate Investment Trusts
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CLPR Real Estate
- COEP Health Care
- Exchange
- CLPR Nasdaq
- COEP Nasdaq
- Market Cap
- CLPR 67.0M
- COEP 72.1M
- IPO Year
- CLPR 2017
- COEP N/A
- Fundamental
- Price
- CLPR $3.70
- COEP $15.87
- Analyst Decision
- CLPR
- COEP
- Analyst Count
- CLPR 0
- COEP 0
- Target Price
- CLPR N/A
- COEP N/A
- AVG Volume (30 Days)
- CLPR 53.2K
- COEP 43.1K
- Earning Date
- CLPR 11-13-2025
- COEP 11-14-2025
- Dividend Yield
- CLPR 10.38%
- COEP N/A
- EPS Growth
- CLPR N/A
- COEP N/A
- EPS
- CLPR N/A
- COEP N/A
- Revenue
- CLPR $154,179,000.00
- COEP $500,996.00
- Revenue This Year
- CLPR N/A
- COEP N/A
- Revenue Next Year
- CLPR N/A
- COEP N/A
- P/E Ratio
- CLPR N/A
- COEP N/A
- Revenue Growth
- CLPR 5.90
- COEP N/A
- 52 Week Low
- CLPR $3.39
- COEP $2.31
- 52 Week High
- CLPR $6.49
- COEP $19.19
- Technical
- Relative Strength Index (RSI)
- CLPR 43.07
- COEP 57.02
- Support Level
- CLPR $3.66
- COEP $13.65
- Resistance Level
- CLPR $3.86
- COEP $17.13
- Average True Range (ATR)
- CLPR 0.16
- COEP 1.16
- MACD
- CLPR -0.01
- COEP 0.19
- Stochastic Oscillator
- CLPR 29.55
- COEP 73.85
About CLPR Clipper Realty Inc.
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.